REC Ref:12/LO/0393EudraCT:2011-005606-30Clinical Trials Gov NCT01712945Full Title:Keratinocyte Growth Factor - promoting thymicreconstitution and preventing autoimmunity after alemtuzumabCampath-1H) treatment ofmultiple sclerosis.Short Title:CAM-THYFunding: Medical research Council and the Moulton FoundationEU Clinical Trials Register
What is the rationale of the “CAM-THY” trial?
We have shown that lymphocyte reconstitution after alemtuzumab isvia expansion of peripheral lymphocytes. We are testing whetherpromotion of thymic reconstitution will prevent autoimmunity. We areusing human recombinant keratincoyte growth factor, which ismarketed as Palifermin as a treatment of stomatitis associated withchemotherapy. In animals, it effectively promote thymic lymphopoeisis.
•age 18-50•relapsing-remitting mutiple sclerosis,•within ten years of the first symptoms of multiple sclerosis,•EDSS 5.5 or less•at least 2 clinical episodes of MS in the previous 2 years, whichmay have occurred whilst on disease-modifying therapy.
Patient Information Sheet
Patient Information Sheet[Provided here for your reference only. NRES Hampstead has allowedus to publish a downloadable version of this patient infomation sheeton the patient pages of this website.]